NEXI vs. BDRX, PRFX, TCBP, TFFP, SRNE, SMFL, BLPH, SEEL, HSTO, and VAXX
Should you be buying NexImmune stock or one of its competitors? The main competitors of NexImmune include Biodexa Pharmaceuticals (BDRX), PainReform (PRFX), TC Biopharm (TCBP), TFF Pharmaceuticals (TFFP), Sorrento Therapeutics (SRNE), Smart for Life (SMFL), Bellerophon Therapeutics (BLPH), Seelos Therapeutics (SEEL), Histogen (HSTO), and Vaxxinity (VAXX). These companies are all part of the "pharmaceutical products" industry.
NexImmune vs.
Biodexa Pharmaceuticals (NASDAQ:BDRX) and NexImmune (NASDAQ:NEXI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.
Biodexa Pharmaceuticals' return on equity of 0.00% beat NexImmune's return on equity.
17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 9.9% of NexImmune shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Comparatively, 14.9% of NexImmune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
NexImmune received 21 more outperform votes than Biodexa Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Biodexa Pharmaceuticals an outperform vote while only 61.11% of users gave NexImmune an outperform vote.
Biodexa Pharmaceuticals has higher revenue and earnings than NexImmune.
In the previous week, Biodexa Pharmaceuticals had 1 more articles in the media than NexImmune. MarketBeat recorded 1 mentions for Biodexa Pharmaceuticals and 0 mentions for NexImmune. Biodexa Pharmaceuticals' average media sentiment score of 0.00 equaled NexImmune'saverage media sentiment score.
Biodexa Pharmaceuticals presently has a consensus target price of $200.00, indicating a potential upside of 4,445.45%. Given Biodexa Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Biodexa Pharmaceuticals is more favorable than NexImmune.
Biodexa Pharmaceuticals has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, NexImmune has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500.
Summary
Biodexa Pharmaceuticals beats NexImmune on 10 of the 13 factors compared between the two stocks.
Get NexImmune News Delivered to You Automatically
Sign up to receive the latest news and ratings for NEXI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NexImmune Competitors List
Related Companies and Tools
This page (NASDAQ:NEXI) was last updated on 1/21/2025 by MarketBeat.com Staff
Free NEXI Stock Alerts